scholarly journals Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 227
Author(s):  
Rosa Papadopoli ◽  
Caterina De Sarro ◽  
Carlo Torti ◽  
Claudia Pileggi ◽  
Maria Pavia
Keyword(s):  
Immune Response ◽  
Booster Dose ◽  
Immunological Response ◽  
Hepatitis B Vaccination ◽  
Anamnestic Response ◽  
Hbv Vaccine ◽  
Vaccine Booster ◽  
Study Population ◽  
Healthcare Professions ◽  
Medical And Healthcare

Whether the primary Hepatitis B vaccination confers lifelong protection is debated. The aim of the study was to assess the effectiveness of booster doses in mounting a protective HBV immune response in subjects vaccinated 18–20 years earlier. The study population consisted of vaccinated students attending medical and healthcare professions schools. A booster dose was offered to subjects with a <10 mIU/mL anti-HBs titer. The post-booster anti-HBs titer was evaluated after four weeks. The subjects with a <10 mIU/mL post-booster anti-HBs titer, received a second and third dose of the vaccine and after one month they were retested. A <10 mIU/mL anti-HBs titer was found in 35.1% of the participants and 92.2% of subjects that were boosted had a ≥10 mIU/mL post-booster anti-HBs titer, whereas 7.8% did not mount an anamnestic response. A low post-booster response (10–100 mIU/mL anti-HBs) was significantly more likely in subjects with a <2.00 mIU/mL pre-booster titer compared to those with a 2.00–9.99 mIU/mL pre-booster titer. The anamnestic response was significantly related to the baseline anti-HBs levels. A booster dose of the HBV vaccine may be insufficient to induce an immunological response in subjects with undetectable anti-HBs titers. A booster dose might be implemented when an anamnestic response is still present.

scholarly journals Immune Response Among the Children to Hepatitis B Vaccination: A Community-based Study in Bangladesh

2018 ◽  
Vol 44 (2) ◽  
pp. 103-108
Author(s):  
Mohammad Monir Hossain ◽  
Ahmed Nawsher Alam ◽  
Mahmuda Siddiqua ◽  
Ayesha Siddika ◽  
Afzalun Nessa
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Protective Efficacy ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Breakthrough Infection ◽  
Protective Level ◽  
Hbv Vaccine ◽  
Public Health Burden

Hepatitis B virus infection is a vaccine preventable infection of liver which remains a key public health burden globally. The development of Anti-HBs titre greater than or equal to 10 IU/L is considered as protective immunity and any titre less than 10 IU/L as non-protective following HBV vaccination. There is no comprehensive and authentic data regarding the immune response even 10 years after the integration of the HBV vaccine in to the EPI programme in Bangladesh and specifically, in Brahmonbaria district. The study was also aimed to assess the long term immune response among HBV vaccinated children. Blood sample from 500 vaccinated children were tested for Anti-HBs, and anti-HBc. Sero negative children were given 1 dose of HBV vaccine as a booster. Samples from booster vaccine were taken one month later and tested for anti Hbs titre. Anti HBs titre was found below protective level in about 46.0% (230/500) participants. Sero-protection rate decreased to 72.2% in 5 to 6 years age group which further decreased to 58.3% in 7 to 9 years age group and increased again to 69.5% in 10 to 12 years age group children. On the other hand, the mean anti Hbs titre was 97.72 IU/L initially and then increased with the increasing of age from 165.40 IU/L to 196.67 IU/L. Breakthrough infection of HBV was seen in 1.2% (6/500) participants measuring by anti HBc which indicated protective efficacy of HBV vaccine was about 98.8% (494/500). Sero negative participants were given a booster dose; 93.6% (131/140) participants showed boosting of mean anti HBs titre upto 804.92 IU/L which was below protective level (<10 IU/L) before booster dose. Anti-HBs titre goes below with the increase of age after vaccination. Most of the participants had immunological memory which will boost antibody titre after any exposure, so routine booster dose is not needed. But non-responder to vaccination should screen after primary vaccination because of chance of breakthrough infection.

scholarly journals Immune Response to Hepatitis B Virus Vaccine in Term and Preterm Babies Received as per EPI Schedule

1970 ◽  
Vol 33 (1) ◽  
pp. 1-5
Author(s):  
Sanjoy Kumer Dey ◽  
Zakia Nahar ◽  
Suparna Chowdhury ◽  
M Shahidullah ◽  
Shahana A Rahman
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Poor Responder ◽  
Hbv Vaccine ◽  
B Virus ◽  
Study Population ◽  
Preterm Babies ◽  
Medical University ◽  
Hepatitis B Virus Vaccine

Objective: To determine the immune response of hepatitis B virus (HBV) vaccinegiven according to EPI schedule and to compare the antibody response among termand preterm babies.Setting: EPI centre, Paediatric OPD and Department of Virology, Bangabandhu SheikhMujib Medical University (BSMMU).Duration: May 2006 to April 2007.Study Population: Thirty preterm and thirty term babies who received 3 doses of HBVvaccination according to EPI schedule.Outcome variables: Immune response to HBV vaccine according to gestational age, accordingto birth weight and comparison of immune response among term and preterm babies.Results: Thirty three percent infants were non-responder in all the groups and 50%infants were good responders in 34-36 weeks and above. Total response was 80%among preterm and 86.6% among term infants.Conclusion: Most of the infants showed positive immune response and there was nosignificant difference among term and preterm babies.Key words: Efficacy of HBV vaccine; immune response; poor responder; good responder.DOI: 10.3329/bjch.v33i1.5668Bangladesh Journal of Child Health 2009; Vol.33(1): 1-5

scholarly journals Role of Booster Dose on Antibody Titer after Recombinant Hepatitis B Vaccination

1970 ◽  
Vol 10 (2) ◽  
pp. 67-76 ◽  
Author(s):  
Md Abdul Ahad ◽  
Md Abdul Alim ◽  
Abhijit Guho ◽  
Quazi Tarikul Islam ◽  
Khan Abul Kalam Azad
Keyword(s):  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Booster Dose ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
B Virus ◽  
Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccination for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (e"10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti- HBs titers below the protective level. Immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals.   doi: 10.3329/jom.v10i2.2817 J MEDICINE 2009; 10 : 67-76

Immune response to a booster dose of enhanced potency inactivated polio vaccine administered in association with HBV vaccine in adolescents

Vaccine ◽  
1996 ◽  
Vol 14 (4) ◽  
pp. 267-269 ◽  
Author(s):  
Fabrizio Pregliasco ◽  
Gualtiero Grilli ◽  
Aida Andreassi ◽  
Elisabetta D'Addezio ◽  
Fabio Vacca ◽  
...  
Keyword(s):  
Immune Response ◽  
Booster Dose ◽  
Inactivated Polio Vaccine ◽  
Hbv Vaccine ◽  
Polio Vaccine

scholarly journals Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate

2016 ◽  
Vol 4 (2) ◽  
pp. 219-225 ◽  
Author(s):  
Samia M. Sami ◽  
Iman I. Salama ◽  
Ghada A. Abdel-Latif ◽  
Lobna A. El Etreby ◽  
Ahmed I. Metwally ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Red Sea ◽  
Booster Dose ◽  
Cross Sectional Study ◽  
Hepatitis B Vaccination ◽  
Seroprotection Rate ◽  
Anamnestic Response ◽  
Cross Sectional ◽  
Logistic Analysis

AIM: To assess the long-term effectiveness of hepatitis B virus vaccine and the need for a booster dose among children who received three doses of vaccine during infancy in Red Sea Governorate.METHODS: A cross-sectional study was performed. Interviews with children (9 months to 16 years) and parents were done. Blood samples to assess Hepatitis B markers were tested. Children showing no seroprotection received a booster dose to assess their anamnestic response after four weeks and one year later. RESULTS: None of the participants had evidence of chronic Hepatitis B. The seroprotection rate was 23.3% and it significantly decreased with age. Multivariate logistic analysis revealed that older age was the significant predicting variable for having no seroprotective level, while baseline anti-HBs level < 3.3 IU/L was the predicting variable for not developing early anamnestic response or loss of late anamnestic response. CONCLUSION: Long-term immunity persists among children who received complete series of hepatitis B vaccination during infancy even in absence or reduction of anti-HBs over time. Therefore, a booster dose is not necessary to maintain immunity till the age of sixteen.

scholarly journals Is There any Difference in Antibody Titer Between Children and Adults after Recombinant Hepatitis B Vaccination?

1970 ◽  
Vol 21 (1) ◽  
pp. 1-11
Author(s):  
M Abdul Ahad ◽  
M Abdul Alim ◽  
Abhiji Guho ◽  
ARM Saifuddin Ekram
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antibody Titer ◽  
Booster Dose ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Recombinant Hepatitis ◽  
Protective Level ◽  
B Virus ◽  
Study Population

Hepatitis B virus infection is an important public health problem with significant morbidity and mortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in different parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in EPI schedule since 2005. This study was carried out to assess the seroconversion status among hepatitis B vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and only HBsAg-negative persons were included for estimation of their anti-HBs titer. Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level (≥10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated controls had anti-HBs titers below the protective level. Regarding immune response developed among vaccinated individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and nonresponders respectively. Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose. Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found in 85.88% male and 92.31% female individuals. Vaccinated individuals from lower socioeconomic condition have had comparatively low rate of protective antibody than people from middle and upper classes. Recombinant HB vaccine induces good level of protective immunity among vaccinated persons. The present study showed that the proportion of adults (93.33%) developed level of protective antibody titer was higher than that of children (83.33%). It indicates that there is difference of antibody titer between children and adults after recombinant Hepatitis B vaccination.    doi: 10.3329/taj.v21i1.3210 TAJ 2008; 21(1): 1-11

scholarly journals STUDY OF IMMUNE RESPONSE AFTER HEPATITIS B VACCINATION IN DOCTORS

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
B.L. Meena ◽  
Nikhil Gandhi ◽  
M.P. Sharma
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Vaccination Status ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Seroprotection Rate

Background: Aim of our study was to evaluate the immune response after hepatitis B vaccination and to determine the duration of protective levels of HBsAb titre in doctors. From our study we concluded that hepatitis-B vaccine gives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required in immunocompetent persons after primary vaccination. Method: In this study total 100 doctors of our institution were included who were vaccinated against hepatitis B. Data were obtained regarding age, sex, weight, height, BMI and duration of vaccination period. Doctors with no prior vaccination or incomplete vaccination or those who took booster vaccination were excluded from this study. Results: The mean titre was observed to be higher in 30 to 34 years of age group (584.42±4.03.21) as compared to age group of less than 25 and greater than 40 years. Moreover, males were observed to have higher mean titre as compared to females. (411.64± 417.27 vs 333.66± 431.49) but not statistically significant.  Similar with age and sex, duration of vaccination status was also not statistically significant. When we compared the  duration of vaccination status with  age group , mean titre was more in ≥30 years of age group as compared to <30 years (younger age groups) but statistically significant relation was observed only with the 1 month to <5 years of duration. Conclusion: From our study we concluded that hepatitis-B vaccinegives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required inimmuno-competent persons after primary vaccination. Keywords: HbsAg titre , HepatitsB vaccine , seroprotection rate.

scholarly journals HBV Seroprotection and Anamnestic Response to Booster Vaccination in Pediatric Cancer Survivors

2021 ◽  
Vol 8 ◽  
pp. 2333794X2110334
Author(s):  
Detchvijitr Suwanpakdee ◽  
Wattanee Taweesith ◽  
Chanchai Traivaree ◽  
Piya Rujkijyanont
Keyword(s):  
Hepatitis B ◽  
Cancer Survivors ◽  
Pediatric Cancer ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Immunological Memory ◽  
Health Concern ◽  
Hepatitis B Vaccination ◽  
Anamnestic Response ◽  
Pediatric Cancer Survivors

Hepatitis B is a major global health concern and can be prevented in the era of vaccination. Impaired immunological memory to primary immunization is a common chemotherapy-related complication among cancer survivors. The study aimed to determine protective immunity against hepatitis B virus (HBV) and anamnestic response to booster vaccination. In all, 107 pediatric cancer survivors previously immunized with primary hepatitis B vaccination were enrolled. A hepatitis B booster dose was administered to those with suboptimal seroprotection (anti-HBs < 10 mIU/mL) and 2 additional doses were subsequently administered at 1 and 6 months to those whose anti-HBs remained low. Clinical and serologic parameters were analyzed. Sero-protective rate against HBV (anti-HBs ≥ 10 mIU/mL) among survivors was 20.6% with geometric mean titer (GMT) of 95.7 ± 265.6 mIU/mL. Anamnestic response was 61% after a booster vaccine among those with suboptimal seroprotection and 100% after 2 additional booster doses among those whose anti-HBs remained low. GMTs among those survivors after the First and third booster vaccines were 320.0 ± 412.4 mIU/mL and 826.5 ± 343.8 mIU/mL, respectively. Age at diagnosis was a significant independent risk factor for adequate seroprotection (adjusted OR = 0.84, 95%CI: 0.71-0.99) with a P-value of .034. No associated risk factors to predict optimal anamnestic response to booster vaccination were identified. Loss of immunological memory to primary hepatitis B immunization is an inevitable complication among most pediatric cancer survivors; therefore, assessing adequate seroprotection is essentially required. For those with limited accessibility to serologic tests, completion of full 3-booster-dose series is alternative and highly recommended.

Sign in / Sign up

Export Citation Format

Share Document